Balloon pulmonary angioplasty (BPA) is the invasive alternative treatment (class I recommendation by the European Society of Cardiology/European Respiratory Society) for patients with chronic thromboembolic pulmonary hypertension (CTEPH) not amenable to pulmonary endarterectomy (PEA) [1–4]. Postprocedural lung injury represents one of the most prevalent complications associated with BPA, with rates between 4–10 % [5,6]. The causal mechanism underlying post-BPA lung injury remains elusive. Initia…